shelf(0)

No. 032 · Mind · Nootropic Peptide

Pinealon

EDR peptideGlu-Asp-Arg

B Tier B · Small human studies how tiers work →
  • Not FDA approved
  • WADA ✗ S0
Compare Cite
Fingerprint 3 residues
Pinealon sequence fingerprint
  • Positive charge 1
  • Negative charge 2

Each dot is a residue placed around the ring from N- to C-terminus; its distance from the centre reflects its chemistry.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER B — Human data limited to small, open-label or pharmacokinetic studies.

Human data are limited to small uncontrolled Russian studies (e.g. 32 adults aged 41–83, Adv Gerontol 2015); the rest is in vitro and rodent work, largely from the developer’s group.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Residues
3 amino acids, N→C
Molecular weight
418.4 Da
Formula
C15H26N6O8
Routes studied
Oral, Intranasal, Subcutaneous Routes used in published research
FDA
Not approved
WADA
Prohibited · S0 Non-approved substances
03

Sequence

N → C · 3 residues · hover, tap, or use arrow keys to inspect

04

Overview

A short regulatory tripeptide (Glu-Asp-Arg) developed by Khavinson that targets CNS gene expression. It may support neuroprotective pathways and cognitive preservation during aging.

Research status In vitro and animal studies plus small uncontrolled human studies, mostly published by groups associated with its developers; limited independent replication

05

Mechanism

Pinealon (Glu-Asp-Arg) is a bioregulatory tripeptide that penetrates cell membranes and interacts with DNA to modulate gene expression in neural tissue. It is reported to upregulate antioxidant enzyme expression and neuroprotective pathways while supporting pineal gland melatonin synthesis.

06

Effects reported in research

Reported outcomes, not promises. Human data are limited to small studies, and many of these findings are preclinical.

  • Neuroprotective gene expression modulation
  • Improved cognitive performance in aging
  • Antioxidant activity in brain tissue
  • Supported pineal gland function
07

Safety & unknowns

Limited safety data, mostly from developer-associated publications. No FDA-approved indication. Independent replication of claims is lacking.

Unknowns. No randomized controlled trials have been published. Small studies cannot detect uncommon or long-term harms.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [1]

  1. Clinical trial 2015

    Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission

    Meshchaninov VN, Tkachenko EL, Zharkov SV, et al. Advances in Gerontology (Uspekhi Gerontologii)

    Uncontrolled study in 32 adults aged 41-83 with polymorbidity and organic brain syndrome that assessed biological-age markers after courses of the tripeptides pinealon and vesugen.

    [pubmed]

10

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

11

Cite this entry

$ cite --format=apa

peptidemeta. (2026). Pinealon. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/pinealon/

$ cite --format=bibtex 
@misc{peptidemeta-pinealon,
  title = {Pinealon},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/pinealon/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open